↓ Skip to main content

Prophylactic Cefazolin Dosing and Surgical Site Infections: Does the Dose Matter in Obese Patients?

Overview of attention for article published in Obesity Surgery, September 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
42 Mendeley
Title
Prophylactic Cefazolin Dosing and Surgical Site Infections: Does the Dose Matter in Obese Patients?
Published in
Obesity Surgery, September 2018
DOI 10.1007/s11695-018-3497-0
Pubmed ID
Authors

Zahid Hussain, Colin Curtain, Corinne Mirkazemi, Karl Gadd, Gregory M. Peterson, Syed Tabish R. Zaidi

Abstract

Most surgical prophylaxis guidelines recommend a 3-g cefazolin intravenous dose in patients weighing ≥ 120 kg. However, this recommendation is primarily based on pharmacokinetic studies rather than robust clinical evidence. This study aimed to compare the prevalence of surgical site infections (SSIs) in obese and non-obese patients (body mass index ≥ 30 kg/m2 and < 30 kg/m2), and those weighing ≥ 120 kg and < 120 kg, who received 2- g cefazolin preoperatively. A retrospective case-control study was conducted in adult elective surgical patients. Patients receiving 2- g cefazolin were grouped as obese and non-obese, and by weight (≥ 120 kg or < 120 kg). The 90-day prevalence of SSI and potential contributing factors were investigated. We identified 152 obese (median 134 kg) and 152 non-obese control (median 73 kg) patients. Baseline characteristics were similar between groups, except for an increased prevalence in the obese group of diabetes (35.5% vs 13.2%; p < 0.001) and an American Society of Anaesthesiologists Score of 3 (61.8% vs 17.1%; p < 0.001). While not statistically significant, the prevalence of SSI in the obese group was almost double that in the non-obese group (8.6% vs 4.6%; p = 0.25) and in patients weighing ≥ 120 kg (n = 102) compared to those weighing < 120 kg (n = 202) (9.8% vs 5.0%; p = 0.17). The prevalence of SSI was not significantly increased in obese patients, or those weighing ≥ 120 kg, who received cefazolin 2- g prophylactically; however, trends toward an increase were evident. Large-scale randomised trials are needed to examine whether a 2-g or 3-g cefazolin is adequate to prevent SSI in obese (and ≥ 120 kg) individuals.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 12%
Researcher 4 10%
Professor 3 7%
Student > Doctoral Student 3 7%
Other 2 5%
Other 8 19%
Unknown 17 40%
Readers by discipline Count As %
Medicine and Dentistry 12 29%
Nursing and Health Professions 8 19%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Psychology 1 2%
Business, Management and Accounting 1 2%
Other 0 0%
Unknown 17 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2018.
All research outputs
#15,546,615
of 23,105,443 outputs
Outputs from Obesity Surgery
#2,100
of 3,415 outputs
Outputs of similar age
#214,727
of 342,007 outputs
Outputs of similar age from Obesity Surgery
#36
of 52 outputs
Altmetric has tracked 23,105,443 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,415 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,007 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.